Pfizer-BioNTech win EC nod for XFG-adapted COVID-19 vaccine

Pfizer and BioNTech have secured European Commission marketing authorisation for their 2026-2027 COVID-19 vaccine, reformulated to target the XFG variant of the JN.1 lineage. The authorisation, valid across all 27 EU member states as well as Iceland, Liechtenstein and Norway, follows a recommendation issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on 23 July 2026.

The updated monovalent formula was developed in response to guidance from the EMA's Emergency Task Force (ETF), which in May 2026 recommended that vaccine manufacturers pivot to XFG on the basis that it would provide the strongest protection against currently circulating lineages. The ETF stated that "the evidence suggests that targeting XFG would provide the best protection against COVID-19." The data package submitted by Pfizer and BioNTech included clinical, non-clinical and real-world evidence, supplemented by immunogenicity data demonstrating responses against several contemporary SARS-CoV-2 sublineages, among them XFG.1.1, NB.1.8.1 and PQ.17.

Supply and distribution

Both companies said manufacturing of the XFG-adapted vaccine began at risk ahead of authorisation to ensure supply is available at the onset of the autumn and winter respiratory season. Distribution to EU member states will proceed either through the existing European Commission procurement contract or via individual country procurement arrangements where governments have opted to negotiate separately.

No shipping volumes or delivery timelines were specified in the release. The companies said they have also submitted the updated formula to regulatory authorities elsewhere in the world and are monitoring the epidemiological picture to anticipate further adaptations if needed.

Pfizer and BioNTech noted that more than five billion doses of their COVID-19 vaccines have been distributed globally since the programme launched in 2020, a figure that underscores the scale of the manufacturing and logistics infrastructure the partners have built.

Market and regulatory context

The annual update cycle for COVID-19 vaccines has settled into a rhythm closely resembling the seasonal influenza model, with the EMA's ETF performing a function analogous to that of the WHO's influenza strain selection committee. This regulatory architecture favours incumbents with established rolling-review relationships and at-risk manufacturing capacity, which benefits Pfizer-BioNTech and Moderna, the two mRNA platforms that hold broad EU marketing authorisations.

Competitor Moderna submitted its own XFG-adapted mRNA-1273 candidate to regulators on a similar timeline; the relative speed of each company's supply chain is likely to be a commercial differentiator in markets where vaccine procurement is handled at national rather than EC level. Novavax's protein-subunit platform is also active in Europe, though the company's market share has remained smaller.

Longer term, the durability of the COVID-19 vaccine market will depend on member state booster policies and public uptake rates, both of which have trended downward since 2022. Investors in both companies will be watching autumn vaccination campaign figures closely as a leading indicator of season revenue.